Table 4.

Patients with EF or GLS changes and their peak hs-TnT

Prevention strategy	Sex	Age	Ejection Fraction			Global Strain			Peak hs-TnT
			Pre	C3	End	Pre	C3	End
Dexrazoxane	M	65	60.5	55	55.2	NA	NA	NA	39.37
Dexrazoxane	F	38	57.1	54.7	50.2	−20.8	−20.4	−16.3	11.01
Dexrazoxane	F	43	70.2	65.3	61.1	−25.9	−21.9	−21.9	10.29
Dexrazoxane	F	49	57.7	51.5	51.6	−21.1	−17.5	−16	4.6
Continuous	M	71	61.3	55.4	55.6	−22.9	−19.1	−15.8	44.07
Continuous	F	24	60.7	53.9	55.3	−20.4	−19.6	−18.1	10.77
Continuous	M	40	57.2	49.9	52	−19.3	−18.1	− 19.3	6.13
Cross Over	F	42	62.3	60.2	55.8	−21	−22.4	−20.1	3.76

NA not available, due to technical limitation